Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience

  • Uri Lindner Division of Urology, Department of Surgical Oncology, University Health Network, and Department of Surgery, University of Toronto, Toronto, ON
  • Sangeet Ghai Department of Medical Imaging, University Health Network, Toronto, ON
  • Paula Spensieri Department of Medical Imaging, University Health Network, Toronto, ON
  • Eugen Hlasny Department of Medical Imaging, University Health Network, Toronto, ON
  • Theodorus H. Van der Kwast Department of Pathology, University Health Network, Toronto, ON
  • Stuart A. McCluskey Department of Anesthesia and Pain Management, University Health Network, Toronto, ON
  • Masoom A. Haider Department of Medical Imaging, University Health Network, Toronto, ON
  • Walter Kucharczyk Department of Medical Imaging, University Health Network, Toronto, ON
  • John Trachtenberg Division of Urology, Department of Surgical Oncology, University Health Network, and Department of Surgery, University of Toronto, Toronto, ON

Abstract

The treatment of low-risk prostate cancer is a common clinical dilemma between standard curative whole gland therapy (and its associated quality of life diminishing side effects) and active surveillance (and its low, but real, risk of progression). The goal of focal therapy in low-risk prostate cancer is to achieve the best balance between cancer control and maintenance of quality of life. Magnetic resonance-guided focused ultrasound (MRgFUS) surgery is a non-invasive thermal ablation method that integrates magnetic resonance imaging for target identification, treatment planning and closed-loop control of thermal deposition and focused ultrasound for thermal ablation of the tumour target. This novel transrectal system allows for tumour localization, targeting and monitoring of tumour target ablation in real time, while simultaneously preserving adjacent normal tissue thereby minimizing the side effects of standard curative surgical or radiation therapy. We report the first North American clinical experience of treatment of localized prostate cancer with focal MR-guided transrectal focused ultrasound (clinicaltrial.gov identifier NCT01226576).
Published
2012-12-13
How to Cite
Lindner, U., Ghai, S., Spensieri, P., Hlasny, E., Van der Kwast, T. H., McCluskey, S. A., Haider, M. A., Kucharczyk, W., & Trachtenberg, J. (2012). Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience. Canadian Urological Association Journal, 6(6), e283-6. https://doi.org/10.5489/cuaj.138
Section
Case Report